229. Autoimmune pulmonary alveolar proteinosis
35 clinical trials,   30 drugs   (DrugBank: 8 drugs),   3 drug target genes,   12 drug target pathways

Searched query = "Autoimmune pulmonary alveolar proteinosis", "Congenital pulmonary alveolar proteinosis", "Hereditary pulmonary alveolar proteinosis", "Pulmonary alveolar proteinosis", "PAP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-004078-32-IT
(EUCTR)
16/05/201907/01/2019Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalationAN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Molgramostim Nebuliser solution 300 mcg
INN or Proposed INN: MOLGRAMOSTIM
Savara ApSNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 3Netherlands;France;Greece;Denmark;Russian Federation;Israel;Germany;United Kingdom;Italy
2EUCTR2017-004078-32-GR
(EUCTR)
05/06/201810/05/2018Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalationAN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Molgramostim Nebuliser solution 300 mcg
INN or Proposed INN: MOLGRAMOSTIM
Savara ApSNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 3France;Greece;Denmark;Russian Federation;Israel;Netherlands;Germany;Italy;United Kingdom
3EUCTR2017-004078-32-DE
(EUCTR)
30/05/201818/12/2017Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalationAN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Molgramostim Nebuliser solution 300 mcg
INN or Proposed INN: MOLGRAMOSTIM
Savara ApSNULLNot RecruitingFemale: yes
Male: yes
90Phase 3France;Greece;Denmark;Russian Federation;Israel;Netherlands;Germany;United Kingdom;Italy
4EUCTR2017-004078-32-FR
(EUCTR)
22/03/201818/12/2017Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalationAN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Molgramostim Nebuliser solution 300 mcg
INN or Proposed INN: MOLGRAMOSTIM
Savara ApSNULLNot RecruitingFemale: yes
Male: yes
90Phase 3Denmark;Russian Federation;Israel;Netherlands;Germany;United Kingdom;Italy;France;Greece